系统性红斑狼疮患者血清腺苷脱氨酶活性及其同工酶谱

Serum adenosine deaminase activity and its isoenzyme pattern in patients with systemic lupus erythematosus.

作者信息

Stancíková M, Lukác J, Istok R, Cristalli G, Rovensky J

机构信息

Department of Connective Tissue Biochemistry, University of Camerino, Italy.

出版信息

Clin Exp Rheumatol. 1998 Sep-Oct;16(5):583-6.

PMID:9779308

Abstract

OBJECTIVE

To study the correlation between serum adenosine deaminase (ADA) activity and clinical activity in patients with systemic lupus erythematosus (SLE). The patterns of two ADA isoenzymes, ADA1 and ADA2, were also analysed in healthy controls and patients to determine the source of increased ADA activity in patients.

METHODS

Total serum ADA activity (tADA) was measured spectrophotometrically. The isoenzyme pattern of ADA was analysed by the HPLC method using a specific inhibitor of ADA1, erytro-9-(2-hydroxy-3-nonyl)adenine (EHNA). Disease activity was assessed using the European Consensus Lupus Activity Measurement index (ECLAM).

RESULTS

Serum tADA activity was significantly increased in patients compared to healthy controls (mean +/- SD; 476.9 +/- 145.3 vs 254.0 +/- 98.9 ncat/L, p < 0.001). The isoenzyme analyses showed that the increased total ADA activity in the patients was mainly due to increased ADA2 activity (371.3 +/- 154.8 vs 214.2 +/- 47.9 ncat/L in healthy controls, p < 0.001). The mean values for ADA1 activity in the patients (64.6 +/- 37.9 ncat/L) and healthy controls (69.2 +/- 26.9 ncat/L) were similar. A strong correlation was found between serum ADA activity and disease activity as measured by ECLAM (Spearman's rank correlation coefficient 0.74, p < 0.0001, linear regression coefficient 0.68, p < 0.01).

CONCLUSION

Serum ADA activity is closely associated with SLE activity and appears to be useful as a new disease activity parameter of SLE.

摘要

目的

研究系统性红斑狼疮（SLE）患者血清腺苷脱氨酶（ADA）活性与临床活动度之间的相关性。同时分析健康对照者和患者中两种ADA同工酶ADA1和ADA2的模式，以确定患者ADA活性升高的来源。

方法

采用分光光度法测定血清总ADA活性（tADA）。使用ADA1的特异性抑制剂erytro-9-(2-羟基-3-壬基)腺嘌呤（EHNA），通过高效液相色谱法分析ADA的同工酶模式。采用欧洲狼疮活动度共识测量指数（ECLAM）评估疾病活动度。

结果

与健康对照者相比，患者血清tADA活性显著升高（均值±标准差；476.9±145.3 vs 254.0±98.9 ncat/L，p<0.001）。同工酶分析显示，患者总ADA活性升高主要归因于ADA2活性增加（健康对照者为214.2±47.9 ncat/L，患者为371.3±154.8 ncat/L，p<0.001）。患者和健康对照者的ADA1活性均值（分别为64.6±37.9 ncat/L和69.2±26.9 ncat/L）相似。血清ADA活性与ECLAM测量的疾病活动度之间存在强相关性（Spearman等级相关系数0.74，p<0.0001，线性回归系数0.68，p<0.01）。